TME Alteration in HER2 Positive Breast Cancer

Tumor Microenvironment Alteration During Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer Patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06533670

Enrollment

Registered

2024-08-01

Start date

2024-07-19

Completion date

2026-07-19

Last updated

2026-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Chemotherapy Effect, HER2-positive Breast Cancer

Brief summary

Evaluate for changes in the tumor microenvironment before/during neoadjuvant chemotherapy and after treatment in patients diagnosed with HER2-positive advanced breast cancer and receiving neoadjuvant cancer therapy and surgery for curative purposes.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

i. Adult patients over 18 years of age ii. Patients undergoing curative treatment including neoadjuvant chemotherapy after confirmation of breast cancer without distant metastases iii. Clinical T stage II-IV patients iv. HER2 positive breast cancer patients

Exclusion criteria

If you have other comorbidities that, according to the researcher's judgment, may affect the results of the study

Design outcomes

Primary

Measure	Time frame	Description
tumor microenvironment alteration	6 months	tumor microenvironment changes during neoadjuvant chemotherapy (NAC) for HER2-positive breast cancer.

Countries

South Korea

Outcome results